# OnCo record paper-antonarakis-ar-v7-resistance-nejm-2014 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-antonarakis-ar-v7-resistance-nejm-2014" ;
  schema:name "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer"@en ;
  schema:alternateName "Antonarakis 2014"@en, "AR-V7"@en, "androgen receptor splice variant 7"@en ;
  schema:description "A short form of the androgen receptor, missing the part that the hormone drugs grab onto, can be detected in tumour cells circulating in the blood. Not one man whose cells carried it responded to either enzalutamide or abiraterone."@en ;
  schema:url <https://onco.cc/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/nejmoa1315815>, <https://pubmed.ncbi.nlm.nih.gov/25184630/>, <https://doi.org/10.1056/NEJMoa1315815> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1056/nejmoa1315815> ;
  schema:datePublished "2014"^^xsd:gYear ;
  schema:author "Antonarakis ES, Lu C, Wang H, et al." ;
  onco:related <https://onco.cc/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/>, <https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/>, <https://onco.cc/ideas/idea-bio1-arv7-degrader/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/abiraterone/> ;
  onco:institutions <https://onco.cc/institutions/johns-hopkins/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/rna-splicing/>, <https://onco.cc/pathways/resistance-routes-map/>, <https://onco.cc/pathways/intravasation-ctc-survival/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/radiographic-progression-free-survival/>, <https://onco.cc/terms/neuroendocrine-differentiation/>, <https://onco.cc/terms/ar-v7/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/psa50/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .